Pulmonary Hypertension in Finland: Key Findings from the FINPAH Study (2008–2020)
The FINPAH study offers valuable insights into pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) in Finland, analyzing data from 2008 to 2020. This real-world data serves as a critical resource for improving the diagnosis and management of these conditions.
Key Findings:
- Incidence: 4.0 and 2.9 cases per million per year for PAH and CTEPH, respectively.
- Diagnosis: The median time from symptoms to diagnosis was 1 year for PAH patients.
- Patient Demographics: The mean age at diagnosis for PAH patients was 57, with 73% being women.
- Survival Rates: At 1 year, 91.3%/94.6% survival; at 5 years, 62.6%/79.4% survival for PAH/CTEPH patients.
- Treatment Impact: Pulmonary endarterectomy (PEA) patients had better survival rates than non-PEA CTEPH patients.
The study underscores the importance of early diagnosis, treatment guidelines, and treatment adherence to improve patient outcomes and aligns with international trends in PAH and CTEPH management.
Picture: Stock Images